About this episode
Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper, Maya Buch and colleagues examined extended MACE endpoints with tofacitinib versus TNFi. Our second paper is from Gerd Burmester and colleagues present long-term efficacy and safety data for upadacitinib through five years. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum
Author Interview: Doctor Elise van Mulligen, September 2026
The IMID Forum
Sep 3, 202621:20pending
Discussing RA: Biologic effectiveness and treatment persistence in RA
The IMID Forum
Aug 27, 20268:52pending
Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety
The IMID Forum
Aug 20, 202624:22pending
Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg,...
The IMID Forum
Aug 13, 202626:58pending